tetano
Editor, Senior Moderator
Cell Rep
. 2022 Jan 11;110318.
doi: 10.1016/j.celrep.2022.110318. Online ahead of print.
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
Kylie M Konrath[SUP] 1 [/SUP], Kevin Liaw[SUP] 2 [/SUP], Yuanhan Wu[SUP] 2 [/SUP], Xizhou Zhu[SUP] 2 [/SUP], Susanne N Walker[SUP] 2 [/SUP], Ziyang Xu[SUP] 1 [/SUP], Katherine Schultheis[SUP] 3 [/SUP], Neethu Chokkalingam[SUP] 2 [/SUP], Himanshi Chawla[SUP] 4 [/SUP], Jianqiu Du[SUP] 5 [/SUP], Nicholas J Tursi[SUP] 2 [/SUP], Alan Moore[SUP] 5 [/SUP], Jared Adolf-Bryfogle[SUP] 6 [/SUP], Mansi Purwar[SUP] 2 [/SUP], Emma L Reuschel[SUP] 2 [/SUP], Drew Frase[SUP] 2 [/SUP], Matthew Sullivan[SUP] 7 [/SUP], Benjamin Fry[SUP] 2 [/SUP], Igor Maricic[SUP] 3 [/SUP], Viviane M Andrade[SUP] 3 [/SUP], Christel Iffland[SUP] 8 [/SUP], Max Crispin[SUP] 4 [/SUP], Kate E Broderick[SUP] 3 [/SUP], Laurent M P F Humeau[SUP] 3 [/SUP], Ami Patel[SUP] 2 [/SUP], Trevor R F Smith[SUP] 3 [/SUP], Jesper Pallesen[SUP] 6 [/SUP], David B Weiner[SUP] 2 [/SUP], Daniel W Kulp[SUP] 9 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and in vitro screening, we have incorporated glycans into the receptor-binding domain (RBD) and assessed antigenic profiles. We demonstrate that glycan-coated RBD immunogens elicit stronger neutralizing antibodies and have engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicits potent neutralizing antibodies in guinea pigs, hamsters, and multiple mouse models, including human ACE2 and human antibody repertoire transgenics. RBD nanoparticles induce high levels of cross-neutralizing antibodies against variants of concern with durable titers beyond 6 months. Single, low-dose immunization protects against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of potent and durable coronavirus vaccines.
Keywords: RBD; SARS-CoV-2; SARS-CoV-2 Challenge; computational design; glycans; immune-focusing; nanoparticle; spike; structure-based design; vaccine.
. 2022 Jan 11;110318.
doi: 10.1016/j.celrep.2022.110318. Online ahead of print.
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
Kylie M Konrath[SUP] 1 [/SUP], Kevin Liaw[SUP] 2 [/SUP], Yuanhan Wu[SUP] 2 [/SUP], Xizhou Zhu[SUP] 2 [/SUP], Susanne N Walker[SUP] 2 [/SUP], Ziyang Xu[SUP] 1 [/SUP], Katherine Schultheis[SUP] 3 [/SUP], Neethu Chokkalingam[SUP] 2 [/SUP], Himanshi Chawla[SUP] 4 [/SUP], Jianqiu Du[SUP] 5 [/SUP], Nicholas J Tursi[SUP] 2 [/SUP], Alan Moore[SUP] 5 [/SUP], Jared Adolf-Bryfogle[SUP] 6 [/SUP], Mansi Purwar[SUP] 2 [/SUP], Emma L Reuschel[SUP] 2 [/SUP], Drew Frase[SUP] 2 [/SUP], Matthew Sullivan[SUP] 7 [/SUP], Benjamin Fry[SUP] 2 [/SUP], Igor Maricic[SUP] 3 [/SUP], Viviane M Andrade[SUP] 3 [/SUP], Christel Iffland[SUP] 8 [/SUP], Max Crispin[SUP] 4 [/SUP], Kate E Broderick[SUP] 3 [/SUP], Laurent M P F Humeau[SUP] 3 [/SUP], Ami Patel[SUP] 2 [/SUP], Trevor R F Smith[SUP] 3 [/SUP], Jesper Pallesen[SUP] 6 [/SUP], David B Weiner[SUP] 2 [/SUP], Daniel W Kulp[SUP] 9 [/SUP]
Affiliations
- PMID: 35090597
- DOI: 10.1016/j.celrep.2022.110318
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and in vitro screening, we have incorporated glycans into the receptor-binding domain (RBD) and assessed antigenic profiles. We demonstrate that glycan-coated RBD immunogens elicit stronger neutralizing antibodies and have engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicits potent neutralizing antibodies in guinea pigs, hamsters, and multiple mouse models, including human ACE2 and human antibody repertoire transgenics. RBD nanoparticles induce high levels of cross-neutralizing antibodies against variants of concern with durable titers beyond 6 months. Single, low-dose immunization protects against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of potent and durable coronavirus vaccines.
Keywords: RBD; SARS-CoV-2; SARS-CoV-2 Challenge; computational design; glycans; immune-focusing; nanoparticle; spike; structure-based design; vaccine.